MUMBAI, India and PITTSBURGH, June 27, 2013 /PRNewsServices/ —
Mylan Inc. (Nasdaq: MYL), one of the world’s leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a portfolio of Women’s Care products in India. The portfolio, which initially will consist of eight products, focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome (PMS). This launch builds on Mylan’s launch of a comprehensive portfolio of antiretroviral products in India last year.
Mylan CEO Heather Bresch commented, “The launch of Mylan’s Women’s Care portfolio expands and strengthens our growing commercial platform in India and further delivers on our commitment to provide the world’s population with access to high quality medicine. Women’s Care represents a high-growth therapeutic category in India and an opportunity for Mylan to help satisfy unmet medical needs. More than 85% of women of childbearing age in India suffer from PMS1, approximately one in five pregnancies in Indian women end in miscarriage2, and it is estimated that the number of infertile couples in India is around 12 million3.”
Bresch continued, “A key challenge in Women’s Health continues to be how to address the risks of miscarriages, infertility and nutritional deficiencies. In addition to launching our innovative, high quality product portfolio, Mylan will help to strengthen the capabilities of health care providers in this area through training programs and workshops, working together with the medical community to address areas of concern in women’s health and improve timely access to appropriate high quality treatment.”
Mylan President Rajiv Malik said, “With the addition of the Women’s Care portfolio, Mylan’s commercial platform is increasingly well-positioned to serve the fast growing Indian market. We expect to continue to expand into new therapeutic categories, further expand our field force and leverage our strong distribution capabilities in India to support future product launches.”
This press release includes statements that constitute “forward-looking statements,” including with regard to the company’s growth potential and expansion of its operations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impact of competition; the effect of any changes in customer and supplier relationships; the ability to attract and retain key personnel; changes in economic and financial conditions of the Company’s business; uncertainties and matters beyond the control of management; and the other risks detailed in the company’s periodic filings with the U.S. Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of anti retroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don’t take our word for it. See for yourself. See inside. mylan.com
- Source: Indian Journal of Clinical Practice, Vol. 22, March 2012
- DC Duta textbook of Obstetrics
- Source: United Nations Population Fund Information Booklet on Prevention and Management of Infertility in Primary Healthcare Settings
SOURCE Mylan Inc.
